Chronic Cough Market: By Drug Class (Antihistamines, Corticosteroids, Decongestants, Combination Drugs, Antibiotics, Acid Blockers, and Others), By Route of Administration (Oral, Injections, Inhalations, and Others), By End Users (Hospitals, Clinics, Homecare, Others) and Geography

Chronic Cough Market was valued at USD 6723 million in 2022 and is poised to grow at a CAGR of 8% over 2023-2029. A chronic cough is a cough that lasts eight weeks or longer, and the most common causes include tobacco use, postnasal drip, asthma, and acid reflux. Based on the drug class, the combination drugs segment is anticipated to dominate the market share over the forecast period. According to the report from several studies, the worldwide prevalence of chronic cough was estimated as 9.6%, whereas the incidence rate ranged from 1.16 to 5.70 per 100 person-years. The rising prevalence of chronic cough and increased global healthcare expenditure will act as the chronic cough market growth drivers. However, the high cost of treatment would be the lagging factor for the market. The development of novel technologies for diagnosis and novel drug development to treat chronic cough are opportunities for pharmaceutical companies for market expansion.

Chronic Cough Market Key Developments:

• In Oct 2019, Aurobindo Pharma received final approval from the US FDA to manufacture generic Guaifenesin extended-release tablets, for chronic cough.
• In Jan 2022, the US FDA approved Merck’s Gefapixant, a non-narcotic, oral selective P2X3 receptor antagonist for the treatment of patients with unexplained chronic cough.